National Abstract Competition for SCDAA’s 49th Annual Convention
DEADLINE EXTENDED TO JULY 13!
If you are a researcher, community-based member organization, physician, nurse, social worker or someone working on behalf of people living with sickle cell disease and their families, Sickle Cell Disease Association of America, Inc. would like to highlight your work at the 49th Annual National Convention October 12-16, 2021 (Virtual).
Because the convention will be virtual, those whose abstracts are accepted will have to submit a 5-minute pre-recorded video of their presentation.
Presentations will be judged during “virtual poster walks,” which will include oral Q&A sessions after the video.
To be eligible, abstracts must meet guidelines and be submitted by July 13, 2021. Abstracts will be reviewed and ranked by the national abstract review committee. Abstract finalists will be judged during oral presentations and presented at the gala. “Best Abstract” in each category will be announced at the conclusion of the SCDAA 49th Annual National Convention. Special awards for the best student and trainee abstracts will also be given.
Abstract Link: https://scdaa2021.exordo.com/
Submission Instructions and Guidelines
Abstract text must be written in English and contain the following:
TITLE: Use a concise title typed in CAPITAL LETTERS.
AUTHORS: List authors’ names (First name, middle initial, last name) and institutional affiliations as briefly as possible. (Limit 12 Authors)
ABSTRACT TEXT: Structure text utilizing the following subheadings: Objective, Methods, Results, and Conclusions.
WORD COUNT: 1,000
UPLOAD TABLES/CHARTS: One file per abstract submission (supported documents: “JPG”, “GIF”, “BMP”, “PNG”, “JPEG”).
*Abstracts without results will not be accepted.
Download the Continuing Education Disclosure Form to be submitted with your abstract (Presenting author only)
2021 Topics and Examples
This year’s virtual convention will feature some innovations for the abstract presentations. To help focus the groups, four new topics have been added that are relevant to sickle cell disease in 2021. If your abstract seems to fit more than one category, please select a first choice and a second choice – the abstract judges will decide which category fits best.
|Topic||Examples for sickle cell disease (SCD)|
|Basic Science and Translational Research||Mechanisms of SCD complications, scientific research to create new therapies, medical procedures, or diagnostics. Studies conducted in lab do not have human subjects.|
|Clinical Research||Human subjects research based in the clinic or hospital to study the safety, effectiveness, and/or efficacy of medications, devices or diagnostic products for human use. These may be used for prevention, treatment or diagnosis, or for relieving symptoms of SCD. *|
|Community Based Research||Research that takes place in community settings and involves community members in the design and implementation of research projects and demonstrates respect for the contributions of success that are made by community partners.|
|Psychosocial Research||Research addressing the interrelation of behavioral, social, psychological and other quality of life factors involving SCD. Areas of interest include: Aging, caregiving, employment, health behaviors and fitness, independent living, self-management and technology access. ***|
|COVID-19||About COVID-19 and SCD or sickle trait: Disease, treatment, vaccine, education and/or social impact.|
|Public Health, Policy, and Implementing the NASEM report Sickle Cell Blueprint for Action||Describe real world ways to utilize the NASEM Report to promote SCD in Public Health, improve health policy on SCD, public awareness of SCD and health professional’s awareness of SCD.|
|SCD Global Health||Studies on SCD outside of the USA and/or reports on collaboration in SCD globally. Abstract may address collaborations between American and global partners with the focus on the other country.|
|Sickle Trait||Sickle trait incidence, screening, complications and education.|
Questions? Read our FAQ guide to learn more.